drugset / Trial / NCT02016482

A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis

NCT02016482

Phase 3 Completed 217 enrolled AbbVie
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is being conducted to assess the safety and efficacy of adalimumab in participants with nail psoriasis.

Timeline

Start
2014-01
Primary completion
2015-10
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Adalimumab Monoclonal antibody 40 mg Subcutaneous

Indications